Kamada (NASDAQ:KMDA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kamada (NASDAQ:KMDA) from a buy rating to a strong-buy rating in a report published on Saturday.

A number of other research firms have also recently weighed in on KMDA. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. HC Wainwright boosted their price objective on Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $7.25 on Friday. The stock has a market capitalization of $416.95 million, a price-to-earnings ratio of 20.14, a PEG ratio of 0.75 and a beta of 0.92. The firm’s 50 day simple moving average is $6.88 and its 200-day simple moving average is $7.11. Kamada has a 12 month low of $5.54 and a 12 month high of $9.15.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The firm had revenue of $47.01 million for the quarter, compared to analyst estimates of $154.21 million. Analysts anticipate that Kamada will post 0.23 earnings per share for the current fiscal year.

Institutional Trading of Kamada

A number of hedge funds have recently bought and sold shares of the business. Trexquant Investment LP acquired a new position in shares of Kamada during the 1st quarter worth approximately $82,000. Cubist Systematic Strategies LLC purchased a new position in Kamada during the first quarter worth approximately $206,000. NewEdge Advisors LLC lifted its position in Kamada by 119.9% during the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after buying an additional 28,165 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Kamada during the first quarter worth $497,000. Finally, Jane Street Group LLC purchased a new stake in Kamada in the 1st quarter valued at $582,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.